Abstract
Remote Ischemic Conditioning (RIC) is a novel therapy that potentially activates protective pathways in the ischemic brain.
Here, we present the clinical endpoints, compliance, and patient-reported outcome measures from a randomized shamcontrolled trial investigating the effect of RIC on the rheo-erythrocrine function of red blood cells in patients with acuteischemic stroke (AIS).
Methods:
Patients were randomly assigned to RIC or sham twice daily for seven days. RIC or sham treatment consisted of five cycles, each cycle with five minutes of cuff inflation and five minutes of deflation on one upper extremity (total
treatment time 50 minutes). The Montreal Cognitive Assessment (MoCA) and National Institute of Health Stroke Scale score
(NIHSS) were obtained at baseline and after seven days.
Results
A total of 30 patients with AIS were included, and of these, 12 out of
15 patients assigned to RIC and 14 of 15 patients assigned to Sham completed the study. In the RIC group, the median (IQR)
age was 67 years (52, 73) compared to 60 years (58, 72) in the sham group. We found no evidence of an association between
RIC and improvement in the 7-day neurological outcome: NIHSS, -0.31 (-1.36-0.68), p = 0.51, and MoCA 1.03 (-1.26-3.32) = 0.38.
All 12 patients (100%) in the RIC group and 7 (50%) in the sham group correctly identified which treatment they had received.
The treatment compliance was high, and the majority of patients were willing to continue the treatment once daily for one year.
ClinicalTrials.gov identifier: NCT04266639 (registered 2020-02-12).
Here, we present the clinical endpoints, compliance, and patient-reported outcome measures from a randomized shamcontrolled trial investigating the effect of RIC on the rheo-erythrocrine function of red blood cells in patients with acuteischemic stroke (AIS).
Methods:
Patients were randomly assigned to RIC or sham twice daily for seven days. RIC or sham treatment consisted of five cycles, each cycle with five minutes of cuff inflation and five minutes of deflation on one upper extremity (total
treatment time 50 minutes). The Montreal Cognitive Assessment (MoCA) and National Institute of Health Stroke Scale score
(NIHSS) were obtained at baseline and after seven days.
Results
A total of 30 patients with AIS were included, and of these, 12 out of
15 patients assigned to RIC and 14 of 15 patients assigned to Sham completed the study. In the RIC group, the median (IQR)
age was 67 years (52, 73) compared to 60 years (58, 72) in the sham group. We found no evidence of an association between
RIC and improvement in the 7-day neurological outcome: NIHSS, -0.31 (-1.36-0.68), p = 0.51, and MoCA 1.03 (-1.26-3.32) = 0.38.
All 12 patients (100%) in the RIC group and 7 (50%) in the sham group correctly identified which treatment they had received.
The treatment compliance was high, and the majority of patients were willing to continue the treatment once daily for one year.
ClinicalTrials.gov identifier: NCT04266639 (registered 2020-02-12).
Originalsprog | Dansk |
---|---|
Tidsskrift | Conditioning Medicine |
Vol/bind | 6 |
Nummer | 6 |
Sider (fra-til) | 208-213 |
ISSN | 2577-3240 |
Status | Udgivet - aug. 2024 |